| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 02/21/2002 | WO2002014311A2 Urea compounds and methods of uses |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014291A1 PPARδ ACTIVATORS |
| 02/21/2002 | WO2002014282A1 2-aminopyridine compounds and use thereof as drugs |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014268A1 1-methyl-20-epivitamin d derivative |
| 02/21/2002 | WO2002014262A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | WO2002013872A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/21/2002 | WO2002013865A1 Agents for ameliorating symptoms caused by joint diseases |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013852A1 Vascular relaxation agents |
| 02/21/2002 | WO2002013840A1 Essential oils and chemically related species for the treatment of increased bone resorption |
| 02/21/2002 | WO2002013832A1 Remedial agent for osteoporosis |
| 02/21/2002 | WO2002013824A1 Cyclopentyl modulators of chemokine receptor activity |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013790A1 Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001074314A3 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066597A3 Inflammation-related gene |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001047510A3 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001042225A3 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | WO2000054729A8 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 02/21/2002 | US20020022781 Products and methods for brachytherapy |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022642 As nitric oxide synthase (NOS) inhibitors, used in therapy and prophylaxis of central nervous system disorders, inflammatory disorders, septic shock and other disorders |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022622 Administering effective amount of oxalzole, thiazole or imidazole derivatives to cure diseases associated with protein aging |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022603 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity |
| 02/21/2002 | US20020022218 Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2 |
| 02/21/2002 | US20020022028 Integrin antagonist; bone disorders |
| 02/21/2002 | DE10039998A1 Neue substituierte Diareno-azepin-Derivate als Integrin Liganden New substituted Diareno-azepine derivatives as integrin ligands |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | DE10038700A1 Autologe Bindegewebe, Verfahren zu ihrer Herstellung und ihre Verwendung Autologous connective tissue, processes for their preparation and their use |
| 02/21/2002 | DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
| 02/21/2002 | CA2419985A1 Modulating multiple lineage kinase proteins |
| 02/21/2002 | CA2419790A1 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | CA2419550A1 Substituted pyrazoles |
| 02/21/2002 | CA2419540A1 Substituted pyrazoles |
| 02/21/2002 | CA2419033A1 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | CA2419008A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | CA2418716A1 Integrin binding motif containing peptides and methods of treating skeletal diseases |
| 02/21/2002 | CA2418389A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | CA2418303A1 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | CA2418273A1 Urea compounds and methods of uses |
| 02/21/2002 | CA2418266A1 Novel mitogen activated kinase |
| 02/21/2002 | CA2417846A1 2-aminopyridine compounds and medical use thereof |
| 02/21/2002 | CA2416794A1 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | CA2415353A1 Use of antibodies against specific mhc-peptide complexes |
| 02/21/2002 | CA2387002A1 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/20/2002 | EP1180519A1 Hydrochloride of fused-heterocycle compound |
| 02/20/2002 | EP1180369A1 MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY |
| 02/20/2002 | EP1180159A1 Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders |
| 02/20/2002 | EP1180144A2 Cytoskeleton-associated proteins |
| 02/20/2002 | EP1180140A1 Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway |
| 02/20/2002 | EP1180122A1 Structural models for cytoplasmic domains of transmembrane receptors |
| 02/20/2002 | EP1180101A1 Compounds having cytokine inhibitory activity |
| 02/20/2002 | EP1180100A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/20/2002 | EP1180037A2 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin |
| 02/20/2002 | EP1180028A1 Il-8 receptor antagonists |
| 02/20/2002 | EP1180026A2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 02/20/2002 | EP1180025A1 Il-8 receptor antagonists |
| 02/20/2002 | EP1180018A1 Preparations for the application of anti-inflammatory agents |
| 02/20/2002 | CN1336921A Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/20/2002 | CN1336919A Phenylphenanthridines with PDE-IV inhibiting activity |
| 02/20/2002 | CN1336215A Medicine for treating rheumatism and cold pain and its utilizing method |
| 02/20/2002 | CN1336209A Fracture setting pellet as bone damage treating traditional Chinese medicine |
| 02/20/2002 | CN1336205A Plaster for treating fracture, soft tissue damage and bruise and its prepn |
| 02/20/2002 | CN1336201A Specific medicine for treating bony spur and its usage |
| 02/20/2002 | CN1336196A Transdermal absorbed medicine for treating periarthritis of shoulder joint |
| 02/20/2002 | CN1079249C Traditional Chinese medicine for treating rheumatoid arthritis |
| 02/20/2002 | CN1079245C Pill for treating thign-bone ischemic necrosis |
| 02/19/2002 | USRE37556 Superoxide radical inhibitor |
| 02/19/2002 | US6348602 Cyclic AMP-specific phosphodiesterase inhibitors |
| 02/19/2002 | US6348497 Prosthetic joints by reducing bone degradation |
| 02/19/2002 | US6348468 Pyridazine compounds and compositions containing the same |
| 02/19/2002 | US6348463 Phenylalanine derivatives |
| 02/19/2002 | US6348329 Isolation of polynucleotide sequence codes of polypeptide with amino acid sequences |
| 02/14/2002 | WO2002012523A2 Transduction of chondrocytes using adenoviral vectors |
| 02/14/2002 | WO2002012461A2 Regulation of human membrane-type serine protease |
| 02/14/2002 | WO2002012346A2 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |